These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 677138)

  • 1. Food and Drug Administration's adverse drug reaction monitoring program.
    Lee B; Turner WM
    Am J Hosp Pharm; 1978 Aug; 35(8):929-32. PubMed ID: 677138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacist and adverse drug reaction reporting.
    Pearson K
    Hosp Pharm; 1982 Aug; 17(8):421-2, 427-30. PubMed ID: 10256700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician knowledge, attitudes, and behavior related to reporting adverse drug events.
    Rogers AS; Israel E; Smith CR; Levine D; McBean AM; Valente C; Faich G
    Arch Intern Med; 1988 Jul; 148(7):1596-600. PubMed ID: 3382304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The state of dietary supplement adverse event reporting in the United States.
    Gardiner P; Sarma DN; Low Dog T; Barrett ML; Chavez ML; Ko R; Mahady GB; Marles RJ; Pellicore LS; Giancaspro GI
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):962-70. PubMed ID: 18613260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reaction reporting system: developing a well-monitored program.
    Kilarski DJ; Ziegler B; Coarse J; Buchanan C
    Hosp Formul; 1986 Sep; 21(9):949-52. PubMed ID: 10289704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
    Wysowski DK; Green L
    Obstet Gynecol; 1995 Apr; 85(4):538-42. PubMed ID: 7898829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe Medical Devices Act: management guidance for hospital compliance with the new FDA requirements.
    Alder HC
    Hosp Technol Ser; 1993 Oct; 12(11):1-27. PubMed ID: 10129209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting adverse drug reaction in a small hospital.
    Magee PE; Garrison TJ
    Hospitals; 1976 Jan; 50(2):63-4, 66-7. PubMed ID: 1245331
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse reaction reporting program.
    Knobloch CP
    J Am Vet Med Assoc; 1980 Jan; 176(1):29. PubMed ID: 6892526
    [No Abstract]   [Full Text] [Related]  

  • 13. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The national registry of drug-induced ocular side effects.
    Fraunfelder FT; Meyer SM
    Aust J Ophthalmol; 1984 May; 12(2):129-31. PubMed ID: 6487182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
    Chez RA
    Obstet Gynecol; 1995 Jul; 86(1):154-5. PubMed ID: 7784014
    [No Abstract]   [Full Text] [Related]  

  • 16. Finding value in the U.S. Food and Drug Administration's Fast Track program.
    Reichert JM; Rochon SL; Zhang BD
    Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing an adverse drug reaction reporting program.
    Nelson RW; Shane R
    Am J Hosp Pharm; 1983 Mar; 40(3):445-6. PubMed ID: 6846354
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacy-coordinated program that encourages physician reporting of adverse drug reactions.
    Gilroy GW; Scollins MJ; Gay CA; Harry DJ; Giannuzzi DF
    Am J Hosp Pharm; 1990 Jun; 47(6):1327-33. PubMed ID: 2368726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.